CytRx Identifies RNAi Drug Candidate for Animal Testing, CEO Downplays Significance of Suits | GenomeWeb

CytRx announced last week that it will advance an siRNA into animal studies as a treatment for type II diabetes and obesity, marking the first time the company has decided to pursue in vivo testing of an RNAi drug candidate.

Separately this week, CytRx President and CEO Steven Kriegsman downplayed the significance of two lawsuits filed against him recently in relation to his one-time directorship of software firm AuthentiDate, stating that the suits have no impact on CytRx.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.

In Science this week: new chromatin imaging approach, and more.